5C perceived the action of Tamoxifen to reduce the risk of breast cancer for BRCA2 carriers as something that clinicians 'intuitively understand', and acknowledged that the lack of 'hard data' had 'never stopped anyone doing anything' (quotes 21 and 22, Table 3). Here, BRCA2 is linked to breast carcinoma.